Comments on: Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) https://thegbm.com/novartis-provides-update-on-delpacibart-etedesiran-del-desiran-phase-iii-harbor-study-for-the-treatment-of-myotonic-dystrophy-type-1-dm1/ Business news, opinion, reviews, interviews Tue, 08 Sep 2026 05:00:00 +0000 hourly 1 https://wordpress.org/?v=7.1